274 related articles for article (PubMed ID: 19998243)
41. Metformin in polycystic ovary syndrome.
Diamanti-Kandarakis E; Economou F; Palimeri S; Christakou C
Ann N Y Acad Sci; 2010 Sep; 1205():192-8. PubMed ID: 20840272
[TBL] [Abstract][Full Text] [Related]
42. Dexamethasone reduces androgen levels in metformin-treated patients with polycystic ovary syndrome.
Vanky E; Kjøtrød SB; Maesel A; Bjerve KS; Carlsen SM
Fertil Steril; 2004 Feb; 81(2):459-62. PubMed ID: 14967392
[TBL] [Abstract][Full Text] [Related]
43. Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study.
Kazerooni T; Shojaei-Baghini A; Dehbashi S; Asadi N; Ghaffarpasand F; Kazerooni Y
Fertil Steril; 2010 Nov; 94(6):2208-13. PubMed ID: 20079899
[TBL] [Abstract][Full Text] [Related]
44. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis.
Li XJ; Yu YX; Liu CQ; Zhang W; Zhang HJ; Yan B; Wang LY; Yang SY; Zhang SH
Clin Endocrinol (Oxf); 2011 Mar; 74(3):332-9. PubMed ID: 21050251
[TBL] [Abstract][Full Text] [Related]
45. Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS.
Xing C; Li C; He B
J Clin Endocrinol Metab; 2020 Sep; 105(9):2950-63. PubMed ID: 32490533
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome.
Diamanti-Kandarakis E; Kouli C; Tsianateli T; Bergiele A
Eur J Endocrinol; 1998 Mar; 138(3):269-74. PubMed ID: 9539300
[TBL] [Abstract][Full Text] [Related]
47. Insulin resistance and the long-term consequences of polycystic ovary syndrome.
Bhathena RK
J Obstet Gynaecol; 2011; 31(2):105-10. PubMed ID: 21281021
[TBL] [Abstract][Full Text] [Related]
48. Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients.
Kebapcilar L; Kebapcilar AG; Bilgir O; Taner CE; Bozkaya G; Yildiz Y; Sari I
Gynecol Endocrinol; 2011 Feb; 27(2):91-5. PubMed ID: 20528207
[TBL] [Abstract][Full Text] [Related]
49. Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study.
Orio F; Manguso F; Di Biase S; Falbo A; Giallauria F; Labella D; Tolino A; Lombardi G; Colao A; Palomba S
Eur J Endocrinol; 2007 Jul; 157(1):69-73. PubMed ID: 17609404
[TBL] [Abstract][Full Text] [Related]
50. Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects.
Nardo LG; Rai R
Gynecol Endocrinol; 2001 Oct; 15(5):373-80. PubMed ID: 11727360
[TBL] [Abstract][Full Text] [Related]
51. Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome.
Jensterle M; Kocjan T; Janez A
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1476-81. PubMed ID: 24823465
[TBL] [Abstract][Full Text] [Related]
52. Androgen levels, insulin sensitivity, and early insulin response in women with polycystic ovary syndrome: a long-term follow-up study.
Hudecova M; Holte J; Moby L; Olovsson M; Stridsberg M; Larsson A; Berglund L; Berne C; Sundström Poromaa I
Fertil Steril; 2011 Mar; 95(3):1146-8. PubMed ID: 21036351
[TBL] [Abstract][Full Text] [Related]
53. [Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
Cappelli V; Di Sabatino A; Musacchio MC; De Leo V
Minerva Ginecol; 2013 Aug; 65(4):425-33. PubMed ID: 24051942
[TBL] [Abstract][Full Text] [Related]
54. [Metformin treatment with or without life style changes in patients with polycystic ovary syndrome].
Petrányi G; Zaoura-Petrányi M
Orv Hetil; 2011 Apr; 152(16):628-32. PubMed ID: 21454179
[TBL] [Abstract][Full Text] [Related]
55. Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin.
Koivunen RM; Morin-Papunen LC; Ruokonen A; Tapanainen JS; Martikainen HK
Hum Reprod; 2001 Dec; 16(12):2546-51. PubMed ID: 11726572
[TBL] [Abstract][Full Text] [Related]
56. Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment.
Kilic S; Yilmaz N; Zulfikaroglu E; Erdogan G; Aydin M; Batioglu S
Gynecol Endocrinol; 2011 Sep; 27(9):622-9. PubMed ID: 21105835
[TBL] [Abstract][Full Text] [Related]
57. [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].
Orbetsova M; Kamenov Z; Kolarov G; Zakharieva S; Khristov V; Atanasova I; Shigarminova R; Milcheva B; Genchev G
Akush Ginekol (Sofiia); 2006; 45(7):16-28. PubMed ID: 17489164
[TBL] [Abstract][Full Text] [Related]
58. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses.
Harborne LR; Sattar N; Norman JE; Fleming R
J Clin Endocrinol Metab; 2005 Aug; 90(8):4593-8. PubMed ID: 15886247
[TBL] [Abstract][Full Text] [Related]
59. Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials.
Patel R; Shah G
Curr Med Res Opin; 2017 Sep; 33(9):1545-1557. PubMed ID: 28058854
[TBL] [Abstract][Full Text] [Related]
60. Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome.
Morin-Papunen LC; Koivunen RM; Tomás C; Ruokonen A; Martikainen HK
J Clin Endocrinol Metab; 1998 Jul; 83(7):2566-8. PubMed ID: 9661644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
